Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Position Cut by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC decreased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 98.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 449 shares of the specialty pharmaceutical company’s stock after selling 24,559 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Jazz Pharmaceuticals were worth $55,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of JAZZ. IFP Advisors Inc acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $25,000. Quadrant Capital Group LLC boosted its holdings in shares of Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after acquiring an additional 101 shares during the period. CoreFirst Bank & Trust acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $28,000. Allianz SE acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $29,000. Finally, Jones Financial Companies Lllp boosted its holdings in shares of Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after acquiring an additional 130 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $109.78 on Tuesday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The company’s 50-day moving average price is $115.24 and its two-hundred day moving average price is $122.09. Jazz Pharmaceuticals plc has a 52 week low of $95.49 and a 52 week high of $148.06. The stock has a market cap of $6.77 billion, a PE ratio of 15.46, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The business had revenue of $897.84 million during the quarter, compared to the consensus estimate of $984.16 million. During the same quarter last year, the firm posted $2.68 earnings per share. Jazz Pharmaceuticals’s revenue was down .5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Seamus Mulligan acquired 100,000 shares of the business’s stock in a transaction on Friday, May 9th. The shares were purchased at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the acquisition, the director now owns 100,000 shares in the company, valued at approximately $9,826,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Patricia Carr sold 4,813 shares of the business’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.42, for a total value of $695,093.46. Following the sale, the chief accounting officer now owns 8,237 shares in the company, valued at approximately $1,189,587.54. The trade was a 36.88% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,236 shares of company stock worth $3,956,190. Company insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

JAZZ has been the subject of several analyst reports. JPMorgan Chase & Co. boosted their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Morgan Stanley cut their price objective on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 7th. Robert W. Baird cut their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. Barclays restated an “overweight” rating and set a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Finally, StockNews.com cut shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 15th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $182.79.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.